Find your people Cannabis reform movements and international policy developments worldwide.
A major prospective study is tracking movement, sleep, cognition and daily life in older adults with chronic pain. Its design reflects a better question: does treatment help people function?
Recent studies suggest some prescribed-cannabis patients feel better able to sleep, connect and participate in daily life. The signal is encouraging—but it is not yet proof of cause and effect.
A controlled trial found that 800 mg of CBD reduced neuropathic pain after spinal-cord injury—but the average benefit was modest and the dose was far removed from retail CBD oil.
New US surveillance identified almost 200,000 emergency visits involving cannabinoid hyperemesis syndrome—but a coding change explains much of the apparent jump.
A controlled trial found that oral dronabinol reduced PTSD-related nightmares. The result is important—but it is not evidence that cannabis treats PTSD as a whole.
A controlled trial found that a precise THC/CBD formulation reduced agitation in advanced dementia. The result deserves attention—and careful limits.
Brazil’s regulator has clarified a revised pathway for manufacturing and importing medical cannabis products. The model protects access, but keeps the category deliberately temporary.
A newly published trial protocol will test whether medicinal cannabis improves quality of life and symptom control in advanced cancer. It is promising research, not a result.
As the global cannabis industry expands, so does its environmental footprint. Indoor cultivation is energy-intensive, water use is high, and packaging waste is mounting. Can the industry's growth be reconciled with its environmental responsibilities?
Sleep disturbance is one of the most common reasons patients cite for using medical cannabis. The research paints a complex picture: cannabis can help you fall asleep faster, but it may also alter sleep architecture in ways that matter.
THC and CBD dominate the conversation, but cannabis contains over 100 cannabinoids. CBG, CBN, CBC, and THCV are emerging as therapeutic compounds in their own right. Here's what the research tells us so far.
From Germany to Brazil, the global cannabis reform landscape is shifting rapidly. A roundup of the major policy developments you need to know.
From pain management to mental health, the clinical research pipeline for cannabinoid medicines is more active than ever. Here are the studies to watch.
Clinical research offers encouraging signals, but different conditions, doses and study designs make broad claims about CBD and anxiety premature.
THC-based medicines may help some people with chronic pain, but variable benefits, side effects and limited long-term data demand a measured reading.
Terpenes — the aromatic compounds in cannabis — are emerging as a key area of research with potential therapeutic applications.